Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae

References

• Livermore DM. Clinical significance of beta-lactamase induction and stable derepression in Gram-negative rods. Eur J Clin Microbiol 1987;6:439–45.
   PubMedGoogle Scholar
• Jones RN. Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis 1998;31:461–6.
   PubMed Web of Science ®Google Scholar
• Negri MC, Baquero F. In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants. Clin Microbiol Infect 1998;4:585–8.
   Google Scholar
• Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DH, Johnson MP, et al. Ann Intern Med 1991;115:585–90.
   PubMed Web of Science ®Google Scholar
• Choi SH, Lee JE, Park SJ, Choi SH, Lee SO, Jeong JY, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC β-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 2008;52:995–1000.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002;162:185–90.
   PubMed Web of Science ®Google Scholar
• Hilty M, Sendi P, Seiffert S, Droz S, Perreten V, Hujer AM, et al. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? Int J Antimicrob Agents 2013;41:236–49.
   Google Scholar
• Sanders WE, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996;23:454–61.
   PubMedGoogle Scholar
• Tamma PD, Girdwood SCT, Gopaul R, Tekle T, Roberts AA, Harris AD, et al. The use of cefepime for treating AmpC beta-lactamase-producing enterobacteriaceae. Clin Infect Dis 2013;57:781–8.
   PubMed Web of Science ®Google Scholar
• Bellido F, Pechere JC, Hancock RE. Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae. Antimicrob Agents Chemother 1991; 35:73–8.
   Google Scholar
• Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases. J Antimicrob Chemother 1995;35:75–84.
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, Light B, Pamillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34: 1589–96.
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al, Surviving Sepsis Campaign Guidelines Committee and Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580–637.
   PubMed Web of Science ®Google Scholar
• Clinical Laboratory Standards Institute. Meeting Minutes, January 2011. Available from: http://clsi.org/standards/micro/microbiology-files/ (accessed June 9, 2013).
   Google Scholar
• Hombach M, Bloemberg GV, Böttger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother 2012;67:622–32.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Fasce R, Molinari MP, Rosso R, Di Biago A, et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother 2007;60:433–5.
   PubMed Web of Science ®Google Scholar
• Pai H, Kang CI, Byeon JH, Lee KD, Park WB, Kim HB, et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type beta-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48:3720–8.
   PubMed Web of Science ®Google Scholar
• Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157:531–9.
   PubMed Web of Science ®Google Scholar
• Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38(S4): S341–5.
   Google Scholar
• Eagye KJ, Nicolau DP. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates. Infect Control Hosp Epidemiol 2010; 31:485–90.
   Google Scholar
• McDougall DA, Morton AP, Playford EG. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia. J Antimicrob Chemother 2013;68:457–60.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ. Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review. Expert Rev Anti Infect Ther 2013;11:69–78.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 2005;55: 306–11.
   PubMed Web of Science ®Google Scholar
• Bhargava A, Hayakawa K, Silverman E, Haider S, Alluri KC, Datla S, et al. Risk factors for colonization due to carbapenem-resistant Enterobacteriaceae among patients exposed to long-term acute care and acute care facilities. Infect Control Hosp Epidemiol 2014;35:398–405.
   PubMed Web of Science ®Google Scholar
• Swaminathan M, Sharma S, Poliansky Blash S, Banach DB, Phillips M, LaBombardi V, et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol 2013;34:809–17.
   PubMed Web of Science ®Google Scholar